90 related articles for article (PubMed ID: 14656048)
1. Oncogenic receptor tyrosine kinase in leukemia.
Mizuki M; Ueda S; Matsumura I; Ishiko J; Schwäble J; Serve H; Kanakura Y
Cell Mol Biol (Noisy-le-grand); 2003 Sep; 49(6):907-22. PubMed ID: 14656048
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3.
Masson K; Rönnstrand L
Cell Signal; 2009 Dec; 21(12):1717-26. PubMed ID: 19540337
[TBL] [Abstract][Full Text] [Related]
3. Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis.
Raafat A; Zoltan-Jones A; Strizzi L; Bargo S; Kimura K; Salomon D; Callahan R
Oncogene; 2007 Feb; 26(5):662-72. PubMed ID: 16878155
[TBL] [Abstract][Full Text] [Related]
4. Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.
Roskoski R
Biochem Biophys Res Commun; 2005 Dec; 338(3):1307-15. PubMed ID: 16226710
[TBL] [Abstract][Full Text] [Related]
5. Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers.
Wilczynski SP; Chen YY; Chen W; Howell SB; Shively JE; Alberts DS
Hum Pathol; 2005 Mar; 36(3):242-9. PubMed ID: 15791568
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the activating mutations within the activation loop of leukemia targets Flt-3 and c-Kit based on protein homology modeling.
Torrent M; Rickert K; Pan BS; Sepp-Lorenzino L
J Mol Graph Model; 2004 Oct; 23(2):153-65. PubMed ID: 15363457
[TBL] [Abstract][Full Text] [Related]
7. Roles for deregulated receptor tyrosine kinases and their downstream signaling molecules in hematologic malignancies.
Matsumura I; Mizuki M; Kanakura Y
Cancer Sci; 2008 Mar; 99(3):479-85. PubMed ID: 18177485
[TBL] [Abstract][Full Text] [Related]
8. Hematopoietic receptors of class III receptor-type tyrosine kinases.
Rosnet O; Birnbaum D
Crit Rev Oncog; 1993; 4(6):595-613. PubMed ID: 7506935
[TBL] [Abstract][Full Text] [Related]
9. Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor.
Roskoski R
Biochem Biophys Res Commun; 2005 Nov; 337(1):1-13. PubMed ID: 16129412
[TBL] [Abstract][Full Text] [Related]
10. Tel/PDGFRbeta induces stem cell differentiation via the Ras/ERK and STAT5 signaling pathways.
Dobbin E; Graham C; Corrigan PM; Thomas KG; Freeburn RW; Wheadon H
Exp Hematol; 2009 Jan; 37(1):111-121. PubMed ID: 19100521
[TBL] [Abstract][Full Text] [Related]
11. FLT-3: a new focus in the understanding of acute leukemia.
Markovic A; MacKenzie KL; Lock RB
Int J Biochem Cell Biol; 2005 Jun; 37(6):1168-72. PubMed ID: 15778081
[TBL] [Abstract][Full Text] [Related]
12. Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotype.
Neben K; Schnittger S; Brors B; Tews B; Kokocinski F; Haferlach T; Müller J; Hahn M; Hiddemann W; Eils R; Lichter P; Schoch C
Oncogene; 2005 Feb; 24(9):1580-8. PubMed ID: 15674343
[TBL] [Abstract][Full Text] [Related]
13. Molecular analysis of PDGFRA and PDGFRB genes by rapid single-strand conformation polymorphism (SSCP) in patients with core-binding factor leukaemias with KIT or FLT3 mutation.
Trojani A; Ripamonti CB; Penco S; Beghini A; Nadali G; Di Bona E; Viola A; Castagnola C; Colapietro P; Grillo G; Pezzetti L; Ravelli E; Patrosso MC; Marocchi A; Cuneo A; Ferrara F; Lazzarino M; Pizzolo G; Cairoli R; Morra E
Anticancer Res; 2008; 28(5A):2745-51. PubMed ID: 19035305
[TBL] [Abstract][Full Text] [Related]
14. Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.
Horn S; Bergholz U; Jücker M; McCubrey JA; Trümper L; Stocking C; Bäsecke J
Oncogene; 2008 Jul; 27(29):4096-106. PubMed ID: 18317450
[TBL] [Abstract][Full Text] [Related]
15. KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance.
Zhu MJ; Ou WB; Fletcher CD; Cohen PS; Demetri GD; Fletcher JA
Oncogene; 2007 Sep; 26(44):6386-95. PubMed ID: 17452978
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine phosphorylation regulates maturation of receptor tyrosine kinases.
Schmidt-Arras DE; Böhmer A; Markova B; Choudhary C; Serve H; Böhmer FD
Mol Cell Biol; 2005 May; 25(9):3690-703. PubMed ID: 15831474
[TBL] [Abstract][Full Text] [Related]
17. Abnormal localization and accumulation of FLT3-ITD, a mutant receptor tyrosine kinase involved in leukemogenesis.
Koch S; Jacobi A; Ryser M; Ehninger G; Thiede C
Cells Tissues Organs; 2008; 188(1-2):225-35. PubMed ID: 18303245
[TBL] [Abstract][Full Text] [Related]
18. Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas.
Do I; Araujo ES; Kalil RK; Bacchini P; Bertoni F; Unni KK; Park YK
Pathol Res Pract; 2007; 203(3):127-34. PubMed ID: 17298867
[TBL] [Abstract][Full Text] [Related]
19. [Mutations of the gene coding for the receptor tyrosine kinase FLT3 in acute myeloid leukemia. Significance as the disease-specific molecular marker for diagnosis, prognosis and innovative therapy approaches].
Spiekermann K; Hiddemann W; Schnittger S
Dtsch Med Wochenschr; 2005 Apr; 130(16):1020-5. PubMed ID: 15830315
[No Abstract] [Full Text] [Related]
20. A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy.
Grand FH; Iqbal S; Zhang L; Russell NH; Chase A; Cross NC
Exp Hematol; 2007 Nov; 35(11):1723-7. PubMed ID: 17764812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]